Casey Tansey Acquires 35,572 Shares of Mobia Medical (NASDAQ:MOBI) Stock

Key Points

• Director Casey Tansey purchased 35,572 Mobia Medical shares at an average price of $11.51, investing approximately $409,434 and increasing direct ownership by 15.25% to 268,904 shares.
• Mobia Medical reported quarterly revenue of $13.51 million, up 102.4% year over year, but its $1.10 per-share loss was wider than analysts’ expected $0.83 loss.
• Analyst sentiment is broadly positive, with a “Moderate Buy” consensus and an average price target of $20.75, despite ratings ranging from Buy to Sell.

Mobia Medical, Inc. (NASDAQ:MOBI - Get Free Report) Director Casey Tansey bought 35,572 shares of the business's stock in a transaction dated Thursday, August 13th. The stock was acquired at an average cost of $11.51 per share, for a total transaction of $409,433.72. Following the completion of the acquisition, the director directly owned 268,904 shares in the company, valued at approximately $3,095,085.04. This trade represents a 15.25% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Mobia Medical Price Performance

Shares of NASDAQ:MOBI opened at $11.74 on Tuesday. Mobia Medical, Inc. has a 1-year low of $10.19 and a 1-year high of $15.29. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.80 and a current ratio of 13.28. The firm has a market cap of $390.84 million and a PE ratio of -0.61. The stock's fifty day simple moving average is $12.42.

Mobia Medical (NASDAQ:MOBI - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($1.10) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.27). The business had revenue of $13.51 million for the quarter. The firm's revenue for the quarter was up 102.4% on a year-over-year basis. Sell-side analysts expect that Mobia Medical, Inc. will post -2.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on MOBI shares. Wolfe Research initiated coverage on Mobia Medical in a research note on Tuesday, June 2nd. They set an "outperform" rating for the company. Weiss Ratings assumed coverage on Mobia Medical in a research note on Wednesday, August 12th. They issued a "sell (e-)" rating on the stock. Wall Street Zen raised Mobia Medical from a "sell" rating to a "hold" rating in a report on Sunday, June 14th. Bank of America assumed coverage on Mobia Medical in a report on Tuesday, June 2nd. They issued a "buy" rating and a $16.00 target price on the stock. Finally, Zacks Research upgraded Mobia Medical to a "hold" rating in a research note on Wednesday, June 3rd. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $20.75.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source